Xen2174
The Company's lead
product, Xen2174, is a novel conopeptide analogue for the treatment of
severe pain. Enrolment into an international phase I/II clinical trial
in patients with cancer pain was recently completed and a phase II
study in post-operative pain commenced in September 2008.
FAQ - Frequently asked Questions
Click here to download further information on the Xen2174 program at Xenome.
|
